[Prescription of bisphosphonates in prostate cancer].
The prognosis of metastatic prostate cancer is multifactorial, but one of the major prognostic factors is the presence of bone metastasis related to tumour progression. Treatment strategies include local treatments such as external beam radiotherapy and bone surgery and systemic treatments such as androgen deprivation, chemotherapy and aminobisphosphonates. Bisphosphonates have been shown to decrease the risk of bone metastasis in randomized clinical trials. Aminobisphosphonates also have a preventive action on bone loss induced by androgen deprivation. Aminobisphosphonates are now recommended as preventive treatment at the time of diagnosis of bone metastatic prostate cancer.
Colombel
Marc
M
Service d'urologie et de chirurgie de la transplantation, INSERM 664 et Université Claude-Bernard, Lyon. marc.colombel@chu-lyon.fr
D000284:Administration, Oral; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000517:prevention & control* / Q000556:secondary*; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D018450:Disease Progression; D006801:Humans; D000077557:Ibandronic Acid; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D007267:Injections; D008297:Male; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013997:Time Factors; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D000077557:Ibandronic Acid